THE EFFECT OF DRUG-RELATED PROBLEMS ON THE DECREASE OF HEMOGLOBINE LEVELS IN CANCER PATIENTS

Pratiwi Rukmana Nasution; Urip Harahap; Dairion Gatot

doi:10.22159/ajpcr.2018.v11s1.26592

Authors

Pratiwi Rukmana Nasution Department of Pharmacology, Faculty of Pharmacy, Universitas Sumatera Utara, Medan, Indonesia.
Urip Harahap Department of Pharmacology, Faculty of Pharmacy, Universitas Sumatera Utara, Medan, Indonesia.
Dairion Gatot Department of Pharmacology, Faculty of Pharmacy, Universitas Sumatera Utara, Medan, Indonesia.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11s1.26592

Keywords:

Doxorubicin, Drug-related problems, Hemoglobin

Abstract

Â Objectives: The aim of this study was to determine the effect of drug-related problems (DRPs) on the decrease in hemoglobin levels in cancer patients.

Methods: This study was a prospective cross-sectional study on seven cancer patients at Haji Adam Malik (HAM) Hospital. Patients aged 35 years old and above with any cancer type and stage from April 2017 to July 2017 were included in the study at HAM Hospital Medan. DRPs were analyzed using DRP Registration Form V7.0 Pharmaceutical Care Network Europe. The obtain data were tested using Chi-square test (p<0.05 is considered significant).

Results: The result showed that based on the characteristics of age, the largest group was 46â€“55 years, and based on the suffered stage, the most stage was Stage III with 57.14%. Two DRPs were identified in seven patients. The most prevalent DRPs were the interaction of drug (100%) followed by unwanted drug reaction (85.71%) and the risk of DRPs was decreasing the hemoglobin levels in cancer patients from the median-to-moderate levels.

Conclusion: Drug-related problems are common among cancer patients. Interaction of drug problems and unwanted drug reaction were the most common types of DRPs among cancer patients, and showed that there was a relationship of DRPs on the decrease in hemoglobin levels.

Downloads

Download data is not yet available.

References

ACS. Cancer Facts and Figures. Available from: http://www.cancer. org/acs/groups/content/@research/documents/documet/acspc-047079. [Last retrieved on 2016 Sep 07].

Chorawala MR, Oza PM, Shah GB. Mechanisms of anticancer drugs resistance. Int J Pharm Sci Drug Res 2012;4:1-9.

Antony A, Joel J, Shetty J, Umar N. Identification and analysis of adverse drug reactions associated with cancer chemotherapy in hospitalized patients. Int J Pharm Pharm Sci 2016;8:448-51.

Elisabeth AL, Keiichi F, Muhieddine S. Principles of chemotherapy. Int J Pharm Sci Drug Res 2015;3:146-9.

Yeoh TT, Tay XY, Si P, Chew L. Drug-related problems in elderly patients with cancer receiving outpatient chemotherapy. J Geriatr Oncol 2015;6:280-7.

Fan L. Pharmacodynamics, Pharmacokinetics and Pharmacogenetics Of Doxorubicin in Singaporean Breast Cancer Patients. Available from: http://www.scholarbank.nus.edu.sg/bitstream/handle/10635/20402/ FanL.pdf?sequence=1. [Last retrieved on 2016 Sep 30].

ASHP. ASHP Statement on Pharmaceutical Care. Am J Health Syst Pharm 50:1720-3.

Ussai S, Petelin R, Giordano A, Malinconico M, Cirillo D, Pentimalli F. A pilot study on the impact of known drug- drug interactions in cancer patients. J Exp Clin Cancer Res 2015;6:34-89.

Aslam M, Naveed S, Ahmed A, Abbas Z, Gull I, dan Athar A. Side effects of chemotherapy in cancer patients and evaluation of patients opinion about starvation based differential chemotherapy. J Cancer Ther 2014;5:817-22.

Taylor A, Maxwell P. Hemoglobin level and tumor growth. Am Assoc Cancer Res 2011;7:223-7.

Dicato M. Anemia in cancer: Some pathophysiological aspects. Oncologist 2003;8:19-21.